Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BCTXL | PRESS-RELEASE | neutral | 3/10 | BriaCell announced the addition of Penn Medicine's Abramson Cancer Center as a clinical trial site for its pivotal Phase | May 13, 2026 |
| ALT | PRESS-RELEASE | neutral | 5/10 | Altimmune reported Q1 2026 EPS of -$0.18, beating the -$0.25 consensus estimate by 28%, though revenue was $0 (vs $1K co | May 13, 2026 |
| ABUS | PRESS-RELEASE | bullish | 8/10 | Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven by $178.7M in licen | May 13, 2026 |
| ABEO | PRESS-RELEASE | neutral | 5/10 | Abeona reported Q1 2026 net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025, with three patients treate | May 13, 2026 |
| KLRA | PRESS-RELEASE | neutral | 4/10 | Kailera Therapeutics and Hengrui Pharma announced two abstracts accepted for poster presentation at the ADA 2026 confere | May 13, 2026 |
| ALT | PRESS-RELEASE | bullish | 6/10 | Altimmune announced that its 48-week IMPACT Phase 2b data for pemvidutide in MASH has been selected for 'Best of EASL 20 | May 13, 2026 |
| MIST | PRESS-RELEASE | neutral | 5/10 | Milestone Pharmaceuticals reported Q1 2026 results with first-ever product revenue of $0.2M from CARDAMYST launch, but n | May 13, 2026 |
| UPB | PRESS-RELEASE | bearish | 6/10 | Upstream Bio reported Q1 2026 EPS of -$0.79, missing consensus of -$0.75 by 5.3%, with net loss widening to $40.6M from | May 13, 2026 |
| KMDA | PRESS-RELEASE | bearish | 7/10 | Kamada reported Q1 2026 EPS of $0.06, a 47.8% miss vs the $0.12 consensus, and revenue of $45.2M (+3% YoY) which was wel | May 13, 2026 |
| AVTX | PRESS-RELEASE | neutral | 6/10 | Avalo Therapeutics reported Q1 2026 results with a net loss of $19.6 million and GAAP EPS of -$0.98, in line with the co | May 13, 2026 |
| BYSI | PRESS-RELEASE | neutral | 4/10 | BeyondSpring reported Q1 2026 financial results showing a net loss from continuing operations of $2.4M, improved from a | May 13, 2026 |
| PDSB | PRESS-RELEASE | neutral | 5/10 | PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/share) in Q1 2025, dri | May 13, 2026 |
| HUMA | PRESS-RELEASE | mixed | 6/10 | Humacyte reported Q1 2026 revenue of $0.5M (vs $1.5M consensus) and EPS of -$0.13 (vs -$0.12 consensus), a miss on both | May 13, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 4/10 | Zenas BioPharma announced first subject dosed in Phase 1 trial of ZB021, an oral IL-17AA/AF inhibitor for autoimmune dis | May 13, 2026 |
| VERU | PRESS-RELEASE | neutral | 5/10 | Veru reported Q2 2026 net loss of $2.7M ($0.12/share), narrower than the $7.9M loss a year ago, driven by lower R&D and | May 13, 2026 |
| APRE | PRESS-RELEASE | neutral | 5/10 | Aprea Therapeutics reported Q1 2026 EPS of -$0.22 (GAAP), beating the -$0.23 consensus by 4.3%, but the headline EPS mis | May 13, 2026 |
| VYGR | PRESS-RELEASE | bullish | 6/10 | Voyager Therapeutics presented positive 3-month GLP toxicology data for VY1706, a tau-silencing gene therapy for Alzheim | May 13, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 5/10 | Zenas BioPharma reported Q1 2026 net loss of $81.0M ($1.46/share), significantly wider than the $33.6M loss a year ago, | May 13, 2026 |
| ELAB | PRESS-RELEASE | neutral | 5/10 | PMGC Holdings acquired A&B Aerospace for $4.5M in cash, marking its fifth acquisition in 12 months as part of a roll-up | May 13, 2026 |
| BBOT | PRESS-RELEASE | neutral | 4/10 | BBOT reported Q1 2026 net loss of $42.1M vs $22.1M a year ago, with R&D spend nearly doubling to $39.8M as three clinica | May 12, 2026 |
| EPRX | PRESS-RELEASE | neutral | 4/10 | Eupraxia reported a Q1 2026 net loss of $12.7M (vs $6.8M a year ago), with cash and short-term investments totaling $138 | May 12, 2026 |
| ZNTL | PRESS-RELEASE | bullish | 7/10 | Zentalis reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with no revenue. The key catalyst is the s | May 12, 2026 |
| IBIO | PRESS-RELEASE | bearish | 6/10 | iBio reported Q3 FY2026 results with EPS of -$0.07 (GAAP) vs consensus -$0.06, a miss of ~16.7%. Revenue was $0, in line | May 12, 2026 |
| AVIR | PRESS-RELEASE | bearish | 5/10 | Atea Pharmaceuticals reported Q1 2026 EPS of -$0.57, a 2.7% miss vs consensus of -$0.56, with net loss widening to $45.4 | May 12, 2026 |
| RZLT | PRESS-RELEASE | neutral | 5/10 | Rezolute reported Q3 fiscal 2026 net loss of $16.2M ($0.16 per share), narrower than the $18.9M loss a year ago, with ca | May 12, 2026 |
| PHVS | PRESS-RELEASE | neutral | 5/10 | Pharvaris reported Q1 2026 EPS of €-0.59 (IFRS), a narrower loss vs €-0.85 a year ago, with cash of €247M extended by a | May 12, 2026 |
| CAPR | PRESS-RELEASE | neutral | 5/10 | Capricor Therapeutics reported Q1 2026 EPS of -$0.59, missing consensus of -$0.54 by ~9.3%, with no revenue. The key cat | May 12, 2026 |
| BOLT | PRESS-RELEASE | bearish | 7/10 | Bolt Biotherapeutics reported Q1 2026 EPS of -$4.31, missing consensus of -$3.60 by 19.7%, and collaboration revenue col | May 12, 2026 |
| LBRX | PRESS-RELEASE | neutral | 4/10 | LB Pharmaceuticals reported Q1 2026 EPS of -$0.67, in line with consensus of -$0.67, and a net loss of $19.1M vs $5.3M a | May 12, 2026 |
| SLDB | PRESS-RELEASE | bearish | 6/10 | Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $5 | May 12, 2026 |